ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Terumo Corp.

  • 7,030.00 JPY
  • +70.00
  • +1.01%
  • Japan
    Mar 22, 2019
  • Ticker
  • Prev. close
  • Market cap (JPY)
  • Market cap (USD)
  • Shares

Business Summary

Terumo Corp. engages in the manufacturing and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan

Financial Highlights

Mar 2018 JPYUSD
Gross Profit305,629M2,757.57M
Operating income106,970M965.15M
Income before tax106,630M962.08M
Net income91,295M823.72M
Diluted EPS242.062.18
Dividends Per Share500.45
Total Assets1,078.98B10,145.56M
Total liabilities528,542M4,969.83M
Total equity550,307M5,174.48M
Operating cash flow114,562M1,033.65M
Currency in JPYCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 467,359M 489,506M 525,026M 514,164M 587,775M
Gross Profit 242,011M 256,026M 284,901M 261,259M 305,629M
Operating income 65,288M 67,456M 81,703M 90,547M 106,970M
Income before tax 52,907M 64,046M 76,920M 74,881M 106,630M
Net income 34,096M 38,470M 50,676M 55,002M 91,295M
EBITDA 105,169M 108,148M 126,377M 125,018M 149,005M
Diluted EPS 89.78 99.12 126.36 142.75 242.06
Dividends Per Share 29 30.50 39 42 50
Total Assets 832,814M 992,073M 901,685M 1,022.26B 1,078.98B
Total liabilities 336,569M 418,550M 390,141M 530,735M 528,542M
Total equity 496,245M 573,523M 511,435M 491,421M 550,307M
Operating cash flow 96,259M 73,110M 80,303M 82,888M 114,562M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 4,665.58M 4,455.86M 4,372.14M 4,748.13M 5,303.27M
Gross Profit 2,415.96M 2,330.54M 2,372.50M 2,412.64M 2,757.57M
Operating income 651.76M 614.03M 680.38M 836.17M 965.15M
Income before tax 528.16M 582.99M 640.55M 691.50M 962.08M
Net income 340.37M 350.18M 422.00M 507.92M 823.72M
EBITDA 1,049.88M 984.44M 1,052.40M 1,154.50M 1,344.41M
Diluted EPS 0.89 0.90 1.05 1.31 2.18
Dividends Per Share 0.28 0.27 0.32 0.38 0.45
Total Assets 8,086.75M 8,272.44M 8,022.46M 9,174.02M 10,145.56M
Total liabilities 3,268.13M 3,490.09M 3,471.15M 4,762.94M 4,969.83M
Total equity 4,818.61M 4,782.34M 4,550.33M 4,410.13M 5,174.48M
Operating cash flow 960.94M 665.50M 668.72M 765.44M 1,033.65M

Valuation Measures

Mar 2018
Operating margin18.19%
Profit margin15.53%

Key executives

  • President, CEO & Representative Director: Shinjiro Sato
  • Chief Accounting & Financial Officer: Ryo Nishihata
  • Chief Clinical & Regulatory Affairs Officer: Kazuhisa Senshu
  • Chief Information Officer & Executive Officer: Katsuya Takeuchi
  • CTO, Executive Officer, Head-R&D Promotions: Hiroaki Kasukawa


  • Nomura Asset Management Co., Ltd. (7.3%)
  • Massachusetts Financial Services Co. (6.0%)
  • Dai-ichi Life Holdings, Inc. (4.5%)
  • Nikko Asset Management Co., Ltd. (3.9%)
  • Meiji Yasuda Life Insurance Co. (3.5%)
  • Daiwa Asset Management Co. Ltd. (3.4%)
  • Mitsubishi UFJ Financial Group, Inc. (2.8%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.6%)
  • Terumo Corp. (2.4%)
  • The Vanguard Group, Inc. (2.2%)

Contact Details

  • Website:
  • Address: 2-44-1 Hatagaya, Shibuya-Ku, Tokyo, 151-0072, Japan
  • Phone: +81.3.3374.8111

Related Companies

  • Essen Technology Pte Ltd.
  • TP Estate, Inc.
  • Terumo BCT Caribe CA
  • Terumo BCT Portugal Unipessoal Lda.
  • Terumo Russia LLC
  • Terumo BCT Biotechnologies LLC
  • Terumo Colombia Andina SAS
  • Terumo BCT Colombia SA
  • Terumo BCT Uruguay SA
  • Terumo BCT Peru SAC
  • Terumo Panama International, Inc.
  • Terumo Mauritius Holding Ltd.
  • Terumo India Pvt Ltd.
  • Terumo BCT (Hong Kong) Ltd.
  • Terumo Medical (Shanghai) Co. Ltd.
  • Terumo Vietnam Medical Equipment Co. Ltd.
  • MicroVention Europe SARL
  • PT Terumo Indonesia
  • Terumo Singapore Pte Ltd.
  • Terumo Marketing Philippines, Inc.
  • Terumo BCT Vietnam Co. Ltd.
  • Terumo BCT Latin America SA
  • Terumo Medical de Mexico SA de CV
  • Terumo BCT Mexico SA de CV
  • Terumo Malaysia Sdn. Bhd.
  • Terumo BCT Medical Product Trading (Shanghai) Ltd.
  • Terumo BCT Tecnologia Medica Ltda.
  • Terumo Vietnam Co. Ltd.
  • Terumo China (Hong Kong) Ltd.
  • Terumo BCT Chile SA


  • Getinge AB Class B
  • Merit Medical Systems, Inc.
  • Fresenius SE & Co. KGaA
  • Fresenius Medical Care AG & Co. KGaA
  • Stryker Corporation
  • InspireMD, Inc.
  • LeMaitre Vascular, Inc.
  • LivaNova Plc
  • CryoLife, Inc.
  • Haemonetics Corporation
  • AngioDynamics, Inc.
  • Lombard Medical Inc
  • Collplant Holdings Ltd
  • Cesca Therapeutics Inc.
  • Penumbra, Inc.
  • Guerbet SA
  • PSB Industries SA
  • BTG plc
  • ABIOMED, Inc.
  • Cellular Biomedicine Group, Inc.
  • Cerus Corporation
  • Nephros, Inc.
  • Retractable Technologies, Inc.
Last Updated on 22 Mar, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media